Norethindrone Acetate And Ethinyl Estradiol Tablet
NDC Package 68462-656-90
Package Information
Norethindrone Acetate And Ethinyl Estradiol tablets are contraindicated in women with any of the following conditions:•Undiagnosed abnormal genital bleeding•Known, suspected, or history of breast cancer •Known or suspected estrogen-dependent neoplasia•Active DVT, PE or a history of these conditions•Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions•Known anaphylactic reaction or angioedema to norethindrone acetate and ethinyl estradiol tablets•Known liver impairment or disease •Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders•Known or suspected pregnancy. This formulation utilizes a tablet delivery system. Marketed by Glenmark Pharmaceuticals Inc., Usa, this product is identified by NDC 68462-656 and is authorized under FDA application ANDA203038.
Identification & Billing
- RxCUI: 1090992 - norethindrone acetate 1 MG / ethinyl estradiol 5 MCG Oral Tablet
- RxCUI: 1090992 - ethinyl estradiol 0.005 MG / norethindrone acetate 1 MG Oral Tablet
- RxCUI: 1090992 - ethinyl estradiol 5 MCG / norethindrone acetate 1 MG Oral Tablet
- RxCUI: 1251323 - norethindrone acetate 0.5 MG / ethinyl estradiol 2.5 MCG Oral Tablet
- RxCUI: 1251323 - ethinyl estradiol 0.0025 MG / norethindrone acetate 0.5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68462 - Glenmark Pharmaceuticals Inc., Usa
- 68462-656 - Norethindrone Acetate And Ethinyl Estradiol
- 68462-656-90 - 90 TABLET in 1 BOTTLE
- 68462-656 - Norethindrone Acetate And Ethinyl Estradiol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68462-656). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68462-656-90 identifies a specific commercial package of 90 tablet in 1 bottle of Norethindrone Acetate And Ethinyl Estradiol, a human prescription drug labeled by Glenmark Pharmaceuticals Inc., Usa. This tablet is formulated for oral use and contains ethinyl estradiol; norethindrone acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glenmark Pharmaceuticals Inc., Usa on April 02, 2015. The current certification is valid through December 31, 2027.
How is this Glenmark Pharmaceuticals Inc., Usa product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68462065690. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.